OUR PIPELINE
ONE VISION. MULTIPLE MODALITIES.
NextPoint’s pipeline is built around a single, unified vision: each therapeutic combines direct tumor killing with immunomodulation.
Our programs target B7-H7 (HHLA2), a molecule central to tumor immune escape and over-expressed in tumors—making it an exceptional target.
By focusing on biology unique to these immune modulators, we are advancing first-in-class therapies with broad potential across multiple solid tumors.
Each molecule is guided by a validated biomarker strategy and designed for optimal specificity, potency and safety.
FIRST-IN-CLASS, MULTIMODAL PRECISION TUMOR TARGETING x IMMUNOMODULATION
Entire Pipeline Supported by Clinical Biomarker to Reach New Patients and Select Responders
NPX372
B7-H7 x CD3
2:1 Bispecific
T Cell Engager
IND Filing Q4 ‘25
NPX125
B7-H7 DAR8 Antibody
Drug Conjugate w/
Novel Linker
IND Filing mid-’26
NPX887
anti-B7-H7 mAb +
TMIGD2 Co-Stim +
Enhanced ADCC
Phase 1
NPX372
B7-H7 x CD3 T Cell Engager
An IgG-like bispecific T cell engager purpose-built to target B7-H7 with a wide therapeutic window. Features include a 2:1 B7-H7:CD3 format, inactivated Fc region, low non-specific cytokine induction and target expression-dependent cytotoxicity. Preclinical studies show complete tumor regression in multiple models. IND filing planned for Q4 2025.
NPX125
B7-H7 Antibody-Drug Conjugate
A DAR8 ADC optimized for tumor payload delivery via Novatecan, a proprietary
linker-payload technology. B7-H7’s internalization profile and tumor-specific expression make it an ideal ADC target. In vivo studies demonstrate complete responses across a range of tumor models. IND filing planned for mid-2026.
NPX887
Tri-Functional B7-H7 Checkpoint Inhibitor
A multi-modal antibody designed to block the inhibitory B7-H7/KIR3DL3 interaction, enhance co-stimulation via TMIGD2, and drive ADCC-mediated tumor killing. Phase 1 clinical trials are underway in patients with B7-H7–positive tumors, including EGFR-mutant NSCLC.
